{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:19Z","timestamp":1791874699104,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012526","name":"Sundhedsvidenskabelige Fakultet, Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012526","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Research Foundation of the Department of Endocrinology and Internal Medicine and the Department of Clinical Epidemiology, Aarhus University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00198-020-05745-x","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T06:04:15Z","timestamp":1609999455000},"page":"1103-1115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7252-8128","authenticated-orcid":false,"given":"A.S.","family":"S\u00f8lling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2693-5651","authenticated-orcid":false,"given":"D.H.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Darvalics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-3523","authenticated-orcid":false,"given":"T.","family":"Harsl\u00f8f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-3474","authenticated-orcid":false,"given":"R.W.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"B.","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"5745_CR1","doi-asserted-by":"crossref","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, Compston J, Cooper C, Stenmark J, McCloskey EV, J\u00f6nsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8(136):1\u20132","DOI":"10.1007\/s11657-013-0136-1"},{"issue":"6","key":"5745_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RGG Russell","year":"2008","unstructured":"Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19(6):733\u2013759","journal-title":"Osteoporos Int"},{"issue":"5","key":"5745_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","volume":"36","author":"AG Porras","year":"1999","unstructured":"Porras AG, Holland SD, Gertz BJ (1999) Pharmacokinetics of alendronate. Clin Pharmacokinet 36(5):315\u2013328","journal-title":"Clin Pharmacokinet"},{"key":"5745_CR4","doi-asserted-by":"crossref","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535\u20131541","DOI":"10.1016\/S0140-6736(96)07088-2"},{"issue":"22","key":"5745_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Br\u00f6ll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333(22):1437\u20131443","journal-title":"N Engl J Med"},{"key":"5745_CR6","doi-asserted-by":"crossref","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927\u20132938","DOI":"10.1001\/jama.296.24.2927"},{"issue":"5","key":"5745_CR7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/jbmr.11","volume":"25","author":"AV Schwartz","year":"2010","unstructured":"Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM, for the FLEX Research Group (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25(5):976\u2013982","journal-title":"J Bone Miner Res"},{"issue":"1","key":"5745_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 29(1):1\u201323","journal-title":"J Bone Miner Res"},{"issue":"10","key":"5745_CR9","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg 72(10):1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"5745_CR10","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1530\/EJE-18-0282","volume":"180","author":"BL Langdahl","year":"2019","unstructured":"Langdahl BL (2019) Management of endocrine disease: treatment breaks in long-term management of osteoporosis. Eur J Endocrinol 180(1):R29\u2013R35","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"5745_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29(8):541\u2013549","journal-title":"Eur J Epidemiol"},{"key":"5745_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449","journal-title":"Clin Epidemiol"},{"key":"5745_CR13","unstructured":"WHO (2010) International statistical classification of diseases and related health problems 10th revision"},{"key":"5745_CR14","doi-asserted-by":"crossref","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M (2017) Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol 46(3):798\u2013798f","DOI":"10.1093\/ije\/dyw213"},{"key":"5745_CR15","doi-asserted-by":"publisher","unstructured":"Zhu D, Chung HF, Pandeya N, Dobson AJ, Cade JE, Greenwood DC, Crawford SL, Avis NE, Gold EB, Mitchell ES, Woods NF, Anderson D, Brown DE, Sievert LL, Brunner EJ, Kuh D, Hardy R, Hayashi K, Lee JS, Mizunuma H, Giles GG, Bruinsma F, Tillin T, Simonsen MK, Adami HO, Weiderpass E, Canonico M, Ancelin ML, Demakakos P, Mishra GD (2018) Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: a pooled analysis of individual data from 17 observational studies. PLoS Med 15(11):e1002704. https:\/\/doi.org\/10.1371\/journal.pmed.1002704","DOI":"10.1371\/journal.pmed.1002704"},{"issue":"4","key":"5745_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, St\u00fcrmer T (2015) The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep 2(4):221\u2013228","journal-title":"Curr Epidemiol Rep"},{"issue":"2","key":"5745_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00198-011-1549-6","volume":"23","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt E, Str\u00f6m O, Robbins S, Borgstr\u00f6m F (2012) Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433\u2013443","journal-title":"Osteoporos Int"},{"key":"5745_CR18","doi-asserted-by":"crossref","unstructured":"Forbes CA, Deshpande S, Sorio-Vilela F, Kutikova L, Duffy S, Gouni-Berthold I, Hagstr\u00f6m E (2018) A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin 34(9):1613\u20131625","DOI":"10.1080\/03007995.2018.1477747"},{"key":"5745_CR19","doi-asserted-by":"crossref","unstructured":"Malo S, Aguilar-Palacio I, Feja C, Lallana MJ, Rabanaque MJ, Armesto J, Menditto E (2017) Different approaches to the assessment of adherence and persistence with cardiovascular-disease preventive medications. Curr Med Res Opin 33(7):1329\u20131336","DOI":"10.1080\/03007995.2017.1321534"},{"key":"5745_CR20","doi-asserted-by":"crossref","unstructured":"Hjelholt TJ, Edwards NM, Vesterager JD, Kristensen PK, Pedersen AB (2020) The positive predictive value of hip fracture diagnoses and surgical procedure codes in the danish multidisciplinary hip fracture registry and the danish national patient registry. Clin Epidemiol 12:123\u2013131","DOI":"10.2147\/CLEP.S238722"},{"key":"5745_CR21","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"5745_CR22","doi-asserted-by":"crossref","unstructured":"Thygesen SK, Christiansen CF, Christensen S, Lash TL, S\u00f8rensen HT (2011) The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11(1):83","DOI":"10.1186\/1471-2288-11-83"},{"key":"5745_CR23","unstructured":"Abrahamsen B (2012) Varigheden af behandling med medicin mod osteoporose. Ration Farmakoter (2)"},{"key":"5745_CR24","doi-asserted-by":"crossref","unstructured":"Nandy S, Parsons S, Cryer C, Underwood M, Rashbrook E, Carter Y, Eldridge S, Close J, Skelton D, Taylor S, Feder G, Falls Prevention Pilot Steering Group (2004) Development and preliminary examination of the predictive validity of the Falls Risk Assessment Tool (FRAT) for use in primary care. J Public Health 26(2):138\u2013143","DOI":"10.1093\/pubmed\/fdh132"},{"key":"5745_CR25","doi-asserted-by":"crossref","unstructured":"Andersen PK, Geskus RB, de Witte T, Putter H (2012) Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 41(3):861\u2013870","DOI":"10.1093\/ije\/dyr213"},{"key":"5745_CR26","doi-asserted-by":"crossref","unstructured":"Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, Fuleihan GE, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV, Task Force of the FRAX Initiative (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22(9):2395\u20132411","DOI":"10.1007\/s00198-011-1713-z"},{"key":"5745_CR27","doi-asserted-by":"crossref","unstructured":"Thygesen LC, Daasnes C, Thaulow I, Br\u00f8nnum-Hansen H (2011) Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 39(7 Suppl):12\u201316","DOI":"10.1177\/1403494811399956"},{"key":"5745_CR28","doi-asserted-by":"crossref","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int J Surg 12(12):1495\u20131499","DOI":"10.1016\/j.ijsu.2014.07.013"},{"key":"5745_CR29","doi-asserted-by":"crossref","unstructured":"Fink HA, Milavetz DL, Palermo L, Nevitt MC, Cauley JA, Genant HK, Black DM, Ensrud KE, Fracture Intervention Trial Research Group (2005) What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Min Res 20(7):1216\u20131222","DOI":"10.1359\/JBMR.050314"},{"key":"5745_CR30","doi-asserted-by":"crossref","unstructured":"Hudson M, Avina-Zubieta A, Lacaille D, Bernatsky S, Lix L, Jean S (2013) The validity of administrative data to identify hip fractures is high - a systematic review. J Clin Epidemiol 66(3):278\u2013285","DOI":"10.1016\/j.jclinepi.2012.10.004"},{"key":"5745_CR31","doi-asserted-by":"crossref","unstructured":"Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19(11):1613\u20131620","DOI":"10.1007\/s00198-008-0604-4"},{"key":"5745_CR32","doi-asserted-by":"crossref","unstructured":"Mignot MA, Taisne N, Legroux I, Cortet B, Paccou J (2017) Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int 28(12):3431\u20133438","DOI":"10.1007\/s00198-017-4215-9"},{"key":"5745_CR33","doi-asserted-by":"crossref","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441","DOI":"10.1056\/NEJM200105103441904"},{"key":"5745_CR34","doi-asserted-by":"crossref","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR , Czerwi\u0144ski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","DOI":"10.1016\/S2213-8587(17)30138-9"},{"key":"5745_CR35","doi-asserted-by":"crossref","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gl\u00fcer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637\u2013645","DOI":"10.1097\/00006254-200001000-00021"},{"key":"5745_CR36","doi-asserted-by":"crossref","unstructured":"Roux C, Reginster J-Y, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z, Luisetto G, Padrino J-Y, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ (2006) Vertebral Fracture Risk Reduction With Strontium Ranelate in Women With Postmenopausal Osteoporosis Is Independent of Baseline Risk Factors. J Bone Min. Res 21(4):536\u2013542","DOI":"10.1359\/jbmr.060101"},{"key":"5745_CR37","unstructured":"Curtis J, et al (2017) The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates. ACR\/ARHP Annunal Meetting 2017, Abstract 828"},{"key":"5745_CR38","doi-asserted-by":"crossref","unstructured":"Curtis JR, Saag KG, Arora T, Wright NC, Yun H, Daigle S, Matthews R, Delzell E (2020) Duration of bisphosphonate drug holidays and associated fracture risk. Med Care 58(5):419\u2013426","DOI":"10.1097\/MLR.0000000000001294"},{"key":"5745_CR39","doi-asserted-by":"crossref","unstructured":"Adams AL, Adams JL, Raebel MA, Tang BT, Kuntz JL, Vijayadeva V, McGlynn EA, Gozansky WS (2018) Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study. J Bone Min Res 33(7):1252\u20131259","DOI":"10.1002\/jbmr.3420"},{"issue":"4","key":"5745_CR40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00198-018-4791-3","volume":"30","author":"S Nayak","year":"2019","unstructured":"Nayak S, Greenspan SL (2019) A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int 30(4):705\u2013720","journal-title":"Osteoporos Int"},{"key":"5745_CR41","doi-asserted-by":"crossref","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9(4):e027049","DOI":"10.1136\/bmjopen-2018-027049"},{"key":"5745_CR42","doi-asserted-by":"crossref","unstructured":"Potteg\u00e5rd A, dePont Christensen R, Houji A, Christiansen CB, Paulsen MS, Thomsen JL, Hallas J (2014) Primary non-adherence in general practice: a Danish register study. Eur J Clin Pharmacol 70(6):757\u2013763","DOI":"10.1007\/s00228-014-1677-y"},{"key":"5745_CR43","doi-asserted-by":"crossref","unstructured":"Hansen C, Pedersen BD, Konradsen H, Abrahamsen B (2013) Anti-osteoporotic therapy in Denmark - predictors and demographics of poor refill compliance and poor persistence. Osteoporos Int 24(7):2079\u20132097","DOI":"10.1007\/s00198-012-2221-5"},{"key":"5745_CR44","doi-asserted-by":"crossref","unstructured":"Adami G, Jaleel A, Curtis JR, Delzell E, Chen R, Yun H, Daigle S, Arora T, Danila MI, Wright NC, Cadarette SM, Mudano A, Foster J, Saag KG (2019) Temporal trends and factors associated with bisphosphonate discontinuation and restart. J Bone Miner Res 35(3):478\u2013487","DOI":"10.1002\/jbmr.3915"},{"key":"5745_CR45","doi-asserted-by":"crossref","unstructured":"Chiha M, Myers LE, Ball CA, Sinacore JM, Camacho PM (2013) Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting. Endocr Pract 19(6):989\u2013994","DOI":"10.4158\/EP12425.OR"},{"key":"5745_CR46","doi-asserted-by":"crossref","unstructured":"Bindon B, Adams W, Balasubramanian N, Sandhu J, Camacho P (2018) Osteoporotic fractures during bisphosphonates drug holiday. Endocr Pract 24(2):163\u2013169","DOI":"10.4158\/EP171975.OR"},{"key":"5745_CR47","doi-asserted-by":"crossref","unstructured":"Hern\u00e1n MA, Robins JM (2017) Per-protocol analyses of pragmatic trials. N Engl J Med 377(5):1391\u20131398","DOI":"10.1056\/NEJMsm1605385"},{"issue":"4","key":"5745_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323\u2013337","journal-title":"J Clin Epidemiol"},{"key":"5745_CR49","unstructured":"Rothman K (2008) Modern Epidemiology, Third edn. Lippincott, Williams, & Wilkins, Philadelphia"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-020-05745-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:07:07Z","timestamp":1621267627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-020-05745-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5745"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05745-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Anne Sophie S\u00f8lling has nothing to disclose.Diana Hedevang Christensen has nothing to disclose.Bianka Darvalics has nothing to disclose.Torben Harsl\u00f8f received lecture fees from Amgen, Astra Zeneca, and Eli Lilly.Reimar Wernich Thomsen has nothing to disclose.Bente Langdahl is an editor-in-chief of Bone Reports and an associate editor of the <i>European Journal of Endocrinology<\/i> and has received research funding to her institution from Amgen and Novo Nordisk. Bente Langdahl serves on advisory boards and speaker\u2019s bureau for Amgen, Eli Lilly, Gedeon-Richter, Gilead, and UCB.The Department of Clinical Epidemiology is involved in studies of osteoporosis with funding from various companies as research grants to (and administered by) Aarhus University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Research Foundation was not involved in the conduct of the study, data collection, interpretation of the data, or the preparation of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Please see supplementary Table  for International Classification of Diseases, Tenth Revision codes, procedure and NOMESCO surgery codes, and Anatomical Therapeutic Chemical classification system codes used in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}